Table 2.

Clinical, pathologic, and survival characteristics of the 59 MIBC

Whole populationRFSOS
Number of patients (%)Number of events (%)aP valuebNumber of events (%)cP valueb
Total population59 (100.0)39 (66.1)34 (57.6)
Age (years)
 ≥6043 (72.8)33 (76.7)0.004630 (69.8)0.002
 <6016 (27.2)6 (37.5)4 (25.0)
Sex
 Male45 (76.3)27 (60.0)0.1526 (57.8)0.97
 Female14 (23.7)12 (85.7)8 (57.1)
Smoking statusd
 Nonsmoker9 (17.0)7 (77.8)0.507 (77.8)0.25
 Smoker44 (83.0)26 (59.1)22 (50.0)
History of NMIBC
 No35 (59.3)21 (60.0)0.2320 (57.1)0.93
 Yes24 (40.7)18 (75.0)14 (58.3)
Associated pTis
 No52 (88.1)36 (69.2)0.2132 (61.5)0.12
 Yes7 (11.9)3 (42.9)2 (28.6)
Tumor stage
 T221 (35.6)13 (61.9)0.618 (38.1)0.024
 ≥T338 (64.4)26 (68.4)26 (68.4)
Lymph node statuse
 N−37 (64.9)20 (54.1)0.01917 (45.9)0.004
 N+20 (35.1)17 (85.0)17 (85.0)
FGFR3 status
 Mutated6 (10.2)4 (66.7)>0.994 (66.7)>0.99
 Not mutated53 (89.9)35 (66.0)30 (56.6)
PIK3CA status
 Mutated6 (10.2)2 (33.3)0.172 (33.3)0.39
 Not mutated53 (89.9)37 (69.8)32 (60.4)
  • NOTE: P < 0.05 are in bold.

  • aFirst recurrence (local or metastatic).

  • bχ2 test, χ2 test with Yates' correction, or Fisher test if appropriate.

  • cDeath.

  • dData available for 53 patients.

  • eData available for 57 patients.